Metagenomi Therapeutics (MGX) Non-Current Assets (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Non-Current Assets of $52.4 million for Q1 2026, down 18.98% year-over-year from $64.7 million in Q1 2025, and down 5.71% quarter-over-quarter from $55.6 million in Q4 2025.
Metagenomi Therapeutics (MGX) Non-Current Assets (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Non-Current Assets for 4 consecutive years, with $52.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 18.98% year-over-year to $52.4 million; the TTM figure through Mar 2026 stood at $226.7 million (down 20.66% YoY), while the FY2025 annual figure was $55.6 million, down 16.62% from the prior year.
- Non-Current Assets declined to $52.4 million in Q1 2026 per MGX's latest filing, from $55.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $86.6 million in Q4 2023 and bottomed at $52.4 million in Q1 2026.
- Historically, Non-Current Assets has averaged $67.9 million across 4 years, with a median of $65.7 million in 2024.
- On a YoY basis, Non-Current Assets climbed as much as 16.62% in 2025 and fell as far as 23.59% in 2025.
- Metagenomi Therapeutics' Non-Current Assets stood at $86.6 million in 2023, then slipped by 23.02% to $66.6 million in 2024, then decreased by 16.62% to $55.6 million in 2025, then retreated by 5.71% to $52.4 million in 2026.
- Business Quant data shows MGX's Non-Current Assets at $52.4 million in Q1 2026, $55.6 million in Q4 2025, and $58.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 49.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.23 Mn |
| Mar 31, 2026 | 52.40 Mn |
| Dec 31, 2025 | 55.57 Mn |
| Sep 30, 2025 | 58.12 Mn |
| Jun 30, 2025 | 60.60 Mn |
| Mar 31, 2025 | 64.67 Mn |
| Dec 31, 2024 | 66.64 Mn |
| Sep 30, 2024 | 76.06 Mn |
| Jun 30, 2024 | 78.33 Mn |
| Mar 31, 2024 | 79.76 Mn |
| Dec 31, 2023 | 86.57 Mn |